Back to Search
Start Over
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.
- Source :
- Current Oncology; Mar2022, Vol. 29 Issue 3, p2021-2045, 25p, 1 Diagram, 13 Charts, 4 Graphs
- Publication Year :
- 2022
-
Abstract
- For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton's tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data. [ABSTRACT FROM AUTHOR]
- Subjects :
- LYMPHOMA treatment
BIOTHERAPY
THERAPEUTIC use of antineoplastic agents
BIOLOGICAL products
CANCER relapse
PROTEIN-tyrosine kinase inhibitors
CANCER patients
TREATMENT effectiveness
COMPARATIVE studies
COST effectiveness
GENE therapy
DESCRIPTIVE statistics
LYMPHOMAS
DRUG resistance in cancer cells
IMMUNOTHERAPY
PALLIATIVE treatment
QUALITY-adjusted life years
Subjects
Details
- Language :
- English
- ISSN :
- 11980052
- Volume :
- 29
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Current Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 156002900
- Full Text :
- https://doi.org/10.3390/curroncol29030164